|
|
|
06/22/10 |
|
AFBC EPIX Pharmaceuticals
Auction - all imaging assets sold |
|
05/21/10 |
|
Epix
Pharmaceuticals, Inc. Announces a Change in the May 28, 2010
Auction Sale of Epix Imaging Agents to June 22, 2010 |
|
05/17/10 |
|
Epix
Pharmaceuticals, Inc. Announces Additional Information
Concerning the May 28, 2010 Auction Sale of EP-3600 MRI
Imaging Agent |
|
05/10/10 |
|
EPIX
Pharmaceuticals, Inc. Announces Additional Information
Concerning the May 28, 2010 Auction Sale of EP-2104R MRI
Imaging Agent |
|
05/04/10 |
|
EPIX
Pharmaceuticals, Inc. Announces the May 28, 2010 Auction
Sale of EP-3600 MRI Imaging Agent |
|
04/19/10 |
|
Epix
Pharmaceuticals, Inc. Announces the May 28, 2010 Auction
Sale of EP-2104R MRI Imaging Agent |
|
04/12/10 |
|
Epix
Pharmaceuticals, Inc. Announces the May 28, 2010 Auction
Sale of MS-325 MRI Imaging Agent |
|
04/05/10 |
|
Epix
Pharmaceuticals, Inc. Announces the May 28, 2010 Auction
Sale of Its MRI Imaging Intellectual Properties |
|
10/22/09 |
|
Joseph F.
Finn, Jr., Assignee for the Benefit of Creditors of EPIX
Pharmaceuticals, Inc.,Releases Statement Regarding
Liquidation Process |
|
10/21/09 |
|
AFBC EPIX Pharmaceuticals
auction |
|
10/16/09 |
|
|
|
10/01/09 |
|
Epix
Pharmaceuticals, Inc. Announces a Successful Auction Sale of
Five Drug Program Intellectual Properties on September 30,
2009 |
|
09/30/09 |
|
AFBC EPIX Pharmaceuticals
auction |
|
09/01/09 |
|
EPIX
Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal
Early Development Candidate Program Will Be Part of the
Intellectual Property Offered For Sale at the September 30,
2009 Auction |
|
08/25/09 |
|
EPIX
Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics
CNS Program in Phase 2b/3 Will Be Part of the Intellectual
Property Offered for Sale at the September 30, 2009 Auction |
|
08/18/09 |
|
Epix
Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics
Program in Phase 2 for Respiratory Indication Will Be Part
of The Intellectual Property Offered for Sale at the
September 30, 2009 Auction |
|
08/13/09 |
|
Epix
Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS
Phase 2 Will be Part of the Intellectual Property Offered
for Sale at the September 30, 2009 Auction |
|
08/04/09 |
|
EPIX Pharmaceuticals,
Inc. Announces August 25, 2009 for the Auction Sale of
Equipment and September 30, 2009 for the Auction Sale of the
Intellectual Property |
|
07/22/09 |
|
EPIX
Pharmaceuticals Inc., Assigns all Its Assets to Joseph F.
Finn Jr., C.P.A. for the Benefit of Its Creditors |
|
07/20/09 |
|
Epix Pharmaceuticals Assigns
Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of
Creditors |
|
|
|
|
|
|
|
|
|
|
06/16/08 |
|
Demandware Awarded n2N Commerce’s Assets in Sealed Bid
Auction |
02/19/08
|
|
n2N SOFTWARE TO BE AUCTIONED APRIL 11, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Prospect Therapeutics Inc.
|
|
06/29/09 |
|
Assets sold |
|
06/22/09 |
|
Prospect Therapeutics Inc.'s GCS-100 Has Focused on
Developing Treatment for Three Blood-Borne Cancers |
|
06/15/09 |
|
Prospect Therapeutics' In Vitro Studies Demonstrate that
GCS-100 Drug Binds to and Blocks the Effects of Galectin-3 |
|
06/05/09 |
|
Ludwig Institute of Cancer Research Ltd., Brussels Branch,
Issues Statement Concerning Prospect Therapeutics Inc's.
GCS-100 Molecule |
|
05/26/09 |
|
Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel
Formation in a Variety of Cancer Models |
|
05/19/09 |
|
Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low
Toxicity Profile in Cancer Patients |
|
05/12/09 |
|
Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph
F. Finn, Jr., C.P.A. for the Benefit of Its Creditors |
|
05/07/09 |
|
Prospect Therapeutics
Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit
of Creditors |
|
06/01/09 |
|
Interim Phase 2 Results On Prospect Therapeutics' GCS-100
Presented At The 10th International Conference On Malignant
Lymphoma |
| |
|
|
| |
|
|
|
10/10/08
|
|
Assets sold
|
09/15/08
|
|
Spherics, Inc. Announces Reduced Cognitive Impairment of
Novel Extended Release Topiramate (SRx-502) as Compared to
Topamax(R)
|
09/09/08
|
|
Spherics, Inc. Announces Sale of Novel Proprietary
Bioadhesive Polymers and Oral Drug Delivery System
|
09/02/08
|
|
Spherics, Inc. Offers Once Daily Extended Release
Formulation for Sustained and Stable Pramipexole Delivery
|
08/25/08
|
|
Spherics, Inc. Offers Extended Release Formulation for
Sustained and Stable Levodopa Levels
|
08/13/08
|
|
Spherics, Inc. Successful Bidder May Make NDA Submission
|
08/04/08
|
|
Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
|